Related Experiment Video
Updated: Jun 14, 2026
The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes
Published on: April 10, 2015
Anticancer Water-Soluble Organoruthenium Complexes: Synthesis and Preclinical Evaluation
Maria Azmanova1, Laia Rafols1, Patricia A Cooper2
1School of Chemistry and Biosciences, University of Bradford, BD7 1DP, Bradford, UK.
Abstract:
The synthesis, characterisation, and evaluation of the in vitro cytotoxicity of five maleonitriledithiolate-based ruthenium metal complexes bearing various phosphine ligands towards two ovarian cancer cell lines (A2780 and A2780cisR), one non-small-cell lung cancer cell line (H460) and one normal prostate cell line (PNT2) are presented herein. These 18-electron complexes were designed with four water-soluble phosphine ligands to increase the water-solubility character of the corresponding electron-deficient ruthenium complex which showed great in vitro promises, and triphenylphosphine for comparison. The complexes with triphenylphosphine-3,3',3''-trisulfonic acid and triphenylphosphine present similar cytotoxicity compared to the 16-electron precursor, with equal cytotoxicity to both A2780 and A2780cisR. Hints at the mechanism of action suggest an apoptotic pathway based on reactive oxygen species (ROS) production. No toxicity was observed in preliminary in vivo pilot studies for these two complexes in subcutaneous A2780 and A2780cisR xenograft models, with some evidence of tumour growth delay.
Insights
Ruthenium complexes with water-soluble phosphine ligands show promise for ovarian cancer treatment. These compounds induce cell death via reactive oxygen species and exhibit no toxicity in preliminary in vivo studies.
Area of Science:
- Inorganic Chemistry
- Medicinal Chemistry
- Cancer Research
Background:
- Ruthenium complexes are investigated for anticancer properties.
- Water-solubility is crucial for effective drug delivery and in vitro evaluation.
- Maleonitriledithiolate ligands offer a scaffold for developing novel metal-based therapeutics.
Purpose of the Study:
- To synthesize and characterize novel ruthenium metal complexes.
- To evaluate the in vitro cytotoxicity of these complexes against various cancer cell lines.
- To explore the mechanism of action and preliminary in vivo efficacy.
Main Methods:
- Synthesis of five maleonitriledithiolate-based ruthenium complexes with diverse phosphine ligands.
- In vitro cytotoxicity assays using ovarian (A2780, A2780cisR), lung (H460), and normal prostate (PNT2) cancer cell lines.
- Mechanism of action studies involving reactive oxygen species (ROS) detection.
- Preliminary in vivo studies using xenograft models.
Main Results:
- Complexes with triphenylphosphine-3,3',3''-trisulfonic acid and triphenylphosphine ligands demonstrated significant in vitro cytotoxicity against ovarian cancer cell lines.
- Cytotoxicity was comparable to the 16-electron precursor and effective against both sensitive and resistant cell lines.
- Evidence suggests apoptosis induction mediated by ROS production.
- Preliminary in vivo studies showed no toxicity and suggested tumor growth delay.
Conclusions:
- Water-soluble ruthenium complexes show potential as anticancer agents, particularly for ovarian cancer.
- The mechanism involves ROS-mediated apoptosis.
- Further investigation into these complexes for cancer therapy is warranted.
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...